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Abstract 
 
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome which frequently accompanies 
acute or chronic liver disease. It is characterized by a variety of symptoms of different 
severity such as cognitive deficits and impaired motor functions. Currently, HE is seen as a 
consequence of a low grade cerebral oedema associated with the formation of cerebral 
oxidative stress and deranged cerebral oscillatory networks. However, the pathogenesis of HE 
is still incompletely understood as liver dysfunction triggers exceptionally complex metabolic 
derangements in the body which need to be investigated by appropriate technologies. This 
review summarizes technological approaches presented at the ISHEN conference 2014 in 
London which may help to gain new insights into the pathogenesis of HE. Dynamic in vivo 
13C nuclear magnetic resonance spectroscopy was performed to analyse effects of chronic 
liver failure in rats on brain energy metabolism. By using a genomics approach, microRNA 
expression changes were identified in plasma of animals with acute liver failure which may be 
involved in interorgan interactions and which may serve as organ-specific biomarkers for 
tissue damage during acute liver failure. Genomics were also applied to analyse glutaminase 
gene polymorphisms in patients with liver cirrhosis indicating that haplotype-dependent 
glutaminase activity is an important pathogenic factor in HE. Metabonomics represents a 
promising approach to better understand HE, by capturing the systems level metabolic 
changes associated with disease in individuals, and enabling monitoring of metabolic 
phenotypes in real time, over a time course and in response to treatment, to better inform 
clinical decision making. Targeted fluxomics allow the determination of metabolic reaction 
rates thereby discriminating metabolite level changes in HE in terms of production, 
consumption and clearance.  
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Abbreviations 
 
ALF;  acute liver failure 
ALI;  acute liver injury 
APAP;  acetaminophen 
BDL;  bile duct-ligation 
CFF;  critical flicker frequency 
CPP;  cerebral perfusion pressure 
DAMP; damage-associated molecular pattern molecules 
GLS;  glutaminase 
HCC;  hepatocellular carcinoma 
HE;   hepatic encephalopathy 
MHE;  minimal hepatic encephalopathy 
miRNA; micro RNA 
MRS;  magnetic resonance spectroscopy 
NMR;  nuclear magnetic resonance 
PHES;  psychometric hepatic encephalopathy score 
TCA;  tricarboxylic acid cycle 
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Bernard Lanz: Effects of chronic hepatic encephalopathy on brain energy metabolism, 
studied by in vivo 13C MRS in rats 
 
 Hepatic encephalopathy is characterized by a wide range of neurological disorders 
which are cascade events initiated by an increase in blood and brain ammonia resulting from 
liver failure. However, the molecular basis for the neurological disorders remains unclear and 
the cause and effect link between the observed disturbances among which changes in amino 
acids concentrations, energy metabolism dysfunction, alteration of oxidative stress, 
mitochondrial permeability transition or neurotransmission and molecular transporters activity 
is still to be determined (Butterworth 2014). 
 Dynamic 13C nuclear magnetic resonance spectroscopy (MRS) is one of the numerous 
in vivo applications of NMR, which is of particular interest for probing brain energy 
metabolism in a non-invasive way (de Graaf et al. 2003; Gruetter 2002; Henry et al. 2006; 
Lanz et al. 2013b; Mason and Rothman 2004). 13C is a stable isotope of carbon present with a 
natural abundance of 1.1% and has a non-zero nuclear magnetic moment, which makes it an 
NMR active nucleus. On the other hand, the most abundant carbon isotope 12C (NA=98.9%) 
has a zero nuclear magnetic moment and therefore cannot be detected through NMR. This 
characteristic can be exploited to probe metabolic processes in vivo by infusing 13C-enriched 
substrates into the studied subject and following the incorporation of the 13C atoms into the 
metabolic products. 
 Following previous ex vivo 13C MRS studies (Bosoi et al. 2014), the presented work 
illustrates the possibilities of in vivo dynamic 13C MRS on a bile duct-ligated (BDL) rat model 
to identify how at later stages of chronic liver disease, increased brain glutamine impacts 
brain oxidative metabolism and glutamate/glutamine cycling.  
 The nowadays availability of horizontal high magnetic field MRS scanners for in vivo 
applications, coupled with strong magnetic field gradients and refined methods for magnetic 
field homogenization (Gruetter and Tkac 2000) enables the measurement of well-resolved 
NMR spectra with temporal resolutions suitable for the analysis of biochemical processes 
involved in oxidative metabolism and neurotransmission (Lanz et al. 2013a) (Fig. 1A). In 
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particular for 13C, the increased sensitivity obtained at high fields such as 9.4T enables the 
measurement of the 13C enrichment turnover of the C4, C3 and C2 positions of glutamate and 
glutamine, resulting from oxidative metabolism of labelled substrates such as [1,6-
13C2]glucose in astrocytic and neuronal tricarboxylic acid (TCA) cycles, as well as carbon 
chain exchanges in glutamatergic neurotransmission processes. The analysis of this dynamic 
13C enrichment using dedicated metabolic models, such as the two-compartment 
neuronal/glial previously applied in this field (Gruetter et al. 2001; Lanz et al. 2013b) enables 
the astrocytic and neuronal TCA cycle fluxes, transmitochondrial exchange with cytosolic 
amino acids as well as apparent glutamatergic neurotransmission and astrocytic anaplerosis.  
 In the present study, eight weeks after surgery, male Wistar rats (n=7 BDL rats, n=5 
sham operated rats) were intravenously infused with [1,6-13C2] glucose under isoflurane 
anaesthesia and in vivo 13C MRS was undertaken over 5 hours at 9.4T, using a semi-adiabatic 
adaption of DEPT polarization transfer for in vivo applications (Henry et al. 2003). This 
sequence enables the localized measurement (320µl voxel) of a wide range of 13C-labeled 
metabolites resulting from glucose metabolism, with the simultaneous advantage of the wide 
chemical shift range of 13C spectra, the precise location based on the low chemical shift 
ranges of the coupled 1H nuclei and the increased measurement sensitivity obtained through 
1H-13C polarization transfer (Fig. 1B). In particular, the 13C enrichment turnover of the C4, C3 
and C2 positions of glutamate and glutamine were measured in terms of fractional enrichment 
with a time resolution of 10 minutes (Fig. 1C). For this purpose, total glutamate and 
glutamine concentrations were determined by 1H MRS prior to the glucose infusion, in the 
same voxel. This represents the first in vivo dynamic 13C MRS measurement of brain 
oxidative metabolism in a chronic liver disease model and will further enable to characterize 
the modifications of the related metabolic fluxes under chronic liver disease (Lanz B., 
unpublished results). 
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Luisa Baker and Fausto Andreola: Increase in plasma levels of brain specific 
microRNA-124-1 associates with falling cerebral perfusion pressure in an 
acetaminophen-induced porcine model of acute liver failure. 
 
Acute liver failure (ALF) is characterized by massive hepatocyte necrosis resulting in 
release of damage-associated molecular pattern molecules (DAMPs), the ensuing 
inflammatory response and multi-organ failure, notably of the kidney and brain (O'Grady et 
al. 1993).  MicroRNAs (miRNAs) are short (ca. 18-25 nucleotides), non-coding stands of 
RNA that function as post-transcriptional regulators by binding to the 3’ untranslated region 
of specific target mRNAs, resulting in repression of translation by promoting mRNA 
degradation or blocking translation (Bartel 2009). MiRNAs are released into the circulation in 
various forms, such as inside exosomes, microvesicles, high-density lipoprotein, apoptotic 
bodies and with proteins (Ago2), and may mediate both short range (cell to cell) and distant 
(to other organs) communication (Szabo and Bala 2013). MiRNAs not released into the 
circulation as naked strands of RNA have been shown to be stable in blood samples, making 
them good candidates for biomarkers (Mitchell et al. 2008).   
In the described study (Baker et al. 2015) a clinically relevant porcine model of 
acetaminophen (APAP)-induced ALF (Lee et al. 2013) was used to investigate temporal 
changes in both global miRNA and tissue-specific miRNAs in plasma samples from induction 
of ALF, through acute liver injury (ALI) and ALF to death.  Six pigs received oral APAP with 
ALF occurring after 19h±2h and death after a further 13h±3h, whilst three control pigs 
underwent the same protocols except for receiving water instead of APAP and were 
maintained for 20h up to ‘ALF’ and 20h thereafter (Fig. 2A).  The study showed significantly 
increased plasma global miRNA levels in the APAP animals starting at 4h before the point of 
ALF (P < 0.0001) and continuing until death, which associated with worsening of clinical 
markers of ALF progression (P < 0.0001); international normalized ratio (INR) (fixed effect 
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(β): 1.904, confidence interval (CI): 1.430-2.378), creatinine (β: 3.323, CI: 2.769-3.878) and 
cerebral perfusion pressure (CPP) (β: -0.080, CI: -0.096 - -0.065).   
To allow quantification of circulating levels of specific miRNA species, which may 
have been contributing to the observed rise in global miRNA levels, miR26a was identified as 
a robust endogenous control.  Plasma levels of three specific miRNA species, miR122, 
miR192 and miR124-1, were quantified.  Liver-specific miR122 increased significantly in the 
plasma around the onset of ALF (P < 0.0001) and associated with increasing INR (P < 
0.0001, β: 3.655, CI: 2.085-5.225).  Plasma levels of kidney-enriched miR192 increased 
significantly 8h after ALF (P < 0.0001) and associated with increasing creatinine (P < 0.0001, 
β: 3.631, CI: 2.329-4.933).  Finally circulating brain-enriched miR124-1 increased 
significantly pre-terminally (P < 0.0001), shortly after plasma ammonia increased and at the 
same time as increasing intracranial pressure and in association with falling CPP (P < 0.002, 
β: -0.041, CI: -0.066 - -0.017).   
To assess whether miRNA were released as a signalling complex or as a result of 
tissue injury, miRNA levels were analysed in isolated plasma exosomes and showed only low 
levels of miRNA that were unaltered by progression of ALF, whilst plasma levels of genomic 
DNA, a DAMP, were significantly elevated from ALF until death (P < 0.0001) and associated 
with plasma global miRNA levels (P < 0.0001, β: 0.613, CI: 0.506-0.719).   
The study concluded that miRNA were released into the plasma as a result of tissue 
injury with global miRNA levels increasing first. Specific miRNA species revealed a timeline 
of organ injury with miR122, miR192 and miR124-1 representing liver, kidney and brain 
injury respectively (Fig. 2B).  Future studies, with a suitable human population, should 
investigate the prognostic potential of global miRNA and tissue-specific miRNA species as 
biomarkers in patients with ALI and ALF. 
 
 
 8 
Javier Ampuero: Application of Genomics in Hepatic Encephalopathy 
 
Genetic tests can be a helpful tool for clinicians to diagnose liver diseases. This is particularly 
true for monogenic diseases. However, for many liver disorders including those outcomes 
derived from liver cirrhosis, multiple genes contribute to the risk of the disease by a 
combination of their phenotypic effects. Moreover, the disease predispositions are 
multifactorial. Most common hepatobiliary liver diseases and traits are complex disorders and 
the level of risk depends on multi-dimensional interactions between genetic and 
environmental factors, which have to be identified. Therefore, refined genome analyses are 
necessary to clarify the link between a typical array of genes with altered expression and the 
risk and severity of HE and further enable the design of polygenic disease predisposition tests.  
 Hepatic encephalopathy (HE) is a major complication of liver cirrhosis with an array 
of clinical manifestations and comprises a spectrum of neuropsychiatric abnormalities 
(Romero-Gomez and Ampuero 2014). HE is graded according to the severity of the 
symptoms. The spectrum of HE encompasses patients with no clinical alterations beyond of 
impairments in neuropsychological and neuropsychiatric tests (minimal HE, (MHE)), patients 
with low-grade or covert HE including MHE and overt HE grade 1, and patients with overt 
HE (typically with grades 2, 3 and 4). West Haven criteria and Glasgow coma scale are 
typically used to determine overt HE, while patients with MHE could be overlooked if not 
systematically investigated with higher sensitivity tests. 
 A wide range of tests have been used to determine the mental status in patients with 
liver cirrhosis (Romero-Gomez and Ampuero 2014), including psychometric (psychometric 
hepatic encephalopathy score, PHES), neuropsychological (critical flicker frequency, CFF) 
and computerized tests, which explore cognition, behaviour, biologic regulation and emotion. 
Using these tools, different neuropsychological stages have been related to MHE, without 
being entirely specific. Recently, Kircheis et al. (Kircheis et al. 2014)  explored the usefulness 
of CFF and PHES in the diagnosis of low-grade HE and illustrated the usefulness of CFF in 
identifying various stages within the spectrum of HE. All these complementary methods help 
to identify patients at risk of suffering overt HE, falls, traffic accidents and impaired quality of 
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life. The results of these tests show a continuum with respect to the severity of HE and require 
therefore the establishment of specific thresholds to define MHE, which remain controversial.  
 HE is resulting from interorgan interactions and systemic hyperammonia plays a major 
role in the pathogenesis of HE (Romero-Gomez et al. 2004). The source of this ammonia 
remains unclear. One possible pathway is glutamine utilization as an energy source by the 
intestinal cells. A genetic factor influencing on the development of overt HE has been 
identified based on the length of alleles (short vs. long) of a microsatellite in 5’UTR promoter 
region of the phosphate-activated glutaminase (GLS) gene and on the presence of TACC 
haplotype (Romero-Gomez et al. 2010). In the current study, patients with cirrhosis were 
divided in two groups based on the presence of TACC haplotype of the glutaminase gene. 
PHES as well as CFF tests (Kircheis et al. 2002; Romero-Gomez et al. 2007) were used as 
MHE evaluation methods. The genetic analyses showed that patients harboring non-TACC 
haplotype had significantly lower events of overt HE with normal CFF results in comparison 
with those with altered CFF, supporting the role of variant GLS in HE development.  On the 
other hand, the TACC haplotype was associated with the absence of overt hepatic 
encephalopathy, irrespective of the result of CFF. This study showed that glutaminase activity 
plays a major role on the overt HE and could influence on the MHE tests (Fig. 3). Evaluation 
of GLS gene should be incorporated to clinical practice as additional screening method. 
 
 
Anisha Wijeyesekera and Elaine Holmes: Application of Metabonomics: The Role of 
Metabolic Profiling in Systems Medicine 
Hepatic encephalopathy is characterized by metabolic derangements, the study of 
which is important to our understanding of the disease process and for the discovery of novel 
treatment options. Metabonomics (defined as the quantitative measurement of time-related 
multi-parametric metabolic responses of multicellular systems to pathophysiological stimuli 
or genetic modification (Nicholson et al. 1999)) offers a unique opportunity to better 
understand HE, by capturing the systems level metabolic changes associated with disease. 
Metabolic profiles can identify both endogenous and exposomic (e.g. drug, food and 
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microbial) metabolites in any biofluid or tissue using a combination of nuclear magnetic 
resonance (NMR) spectroscopy and mass spectrometry (MS), often hyphenated with pre-
separation techniques such as gas chromatography, ultra performance liquid chromatography 
and capillary electrophoresis.  Multivariate pattern recognition analysis of the spectra allows 
identification of chemical signatures associated with disease class or condition, and further 
statistical correlation allows identification of other metabolites that are correlated with a 
particular marker.  This data can then be interpreted by relating it to metabolic pathways and 
integrating it with complementary omics data.  Once marker metabolites of interest have been 
identified, a targeted metabolite assay is developed to capture and quantify those metabolites.   
The potential applications of metabonomics to liver disease research are diverse and 
the following are examples of this work. A recent study applied an untargeted metabolic 
screening approach using NMR spectroscopy to characterise the metabolic phenotype of 
patients with or without cirrhosis, and with or without HE compared to gender and age 
matched healthy controls. The results revealed an increase in lactate and five amino acids in 
HE patients compared with controls; these metabolites are precursors for gluconeogenesis and 
indicative of impaired energy production. Furthermore, ketone bodies were also elevated in 
cirrhotic and HE patients compared with controls; acetoacetate was observed to be higher in 
HE compared to cirrhosis (in comparison with the other ketone bodies -hydroxybutyrate and 
acetate). The authors hypothesise that these findings are indicative of impaired ketogenesis in 
HE (Dabos et al. 2015).  Another study using a similar approach identified changes in amino 
acid and lipid metabolites in plasma from patients with liver fibrosis compared to healthy 
controls (Sands et al. 2015). These changes were indicative of impaired aromatic amino acid 
metabolism, impaired methionine metabolism and altered lipid metabolism with liver fibrosis. 
Metabolic profiling has also been used to investigate the possibility of differentiating 
hepatocellular carcinoma (HCC) from cirrhosis by analysis of urinary metabolites in order to 
allow identification and early treatment of patients with HCC in West Africa, where hepatitis 
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B and C prevalence is high (Ladep et al. 2014).  The study identified six urinary metabolites; 
acetylcarnitine, betaine aldehyde, carnitine, creatine, ribitol and N-acetylglutamate, which 
were increased (P < 0.005) with presence and grade of HCC compared to cirrhosis. In another 
application, a toxicological study investigated the effects of the gut microbiome on 
metabolism of the steatotic hepatotoxin, hydrazine in conventional and germ free rats to 
explore the role of the gut microbiota in mediating liver toxicity (Swann et al. 2009), and 
showed an altered urinary metabolite time trajectory in germ free rats corresponding with 
more severe toxicity and extreme outliers in brain tissue metabolites with severe toxic 
reactions.   
Direct in clinic applications of metabonomics include both longitudinal modelling 
from patient admission through treatment to outcome and real-time modelling from samples 
collected at surgery (Kinross et al. 2011).  Real-time surgical diagnostics is being investigated 
through the use of the intelligent knife (iKnife), a cutting electrocautery head attached to a 
handle that can sample the tissue smoke and run it through a specialized mass spectrometer, 
which in real-time compares the spectrum of the glycerophospholipids to a tissue specific 
database and provides the surgeon with feedback as to the tissue type being cut through.  The 
iKnife is currently undergoing clinical trials but early data suggest good success with margins 
around cancerous tissue (Balog et al. 2013).  Finally next generation technologies combining 
metabonomics and imaging include using matrix-assisted laser desorption/ionization-MS to 
form topographic chemistry images (Fonville et al. 2013) and using desorption electrospray 
ionisation imaging on frozen tissue sections to identify tissue types within the section based 
on co-localisation of optical and metabolite data for each pixel providing a pathway for 
augmenting clinical decision-making (Abbassi-Ghadi et al. 2014; Mirnezami et al. 2014). 
 
Nicolaas Deutz: Targeted fluxomics in humans to measure the synthesis and breakdown 
of biological molecules. 
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Protein and amino acid metabolism are important to the pathogenesis of hepatic 
encephalopathy and the study of changes in metabolite flux during hepatic disease allows 
better understanding of this pathogenesis. Targeted fluxomics involves the measuring of 
specific metabolites at the whole body and organ level to determine metabolic reaction rates. 
Some products that appear in plasma are mainly derived from certain tissue and as such the 
whole body appearance can be used to estimate organ metabolism. A good example is the 
appearance of the amino acid 3-methylhistidine that is product in muscle tissue. When it is 
possible to collect blood across organs or organ tissue like muscle or brain, intracellular 
metabolism can be estimated. 
Several methods have been described to measure the whole body metabolic reaction 
rates. We and others have used the primed constant and continuous infusion protocol with 
tracers of substrates to measure the production of the tracee of the substrate (Rate of 
appearance (Ra)). This approach was also used to measure the conversion of a substrate into a 
product. A well-known metabolic pathways that is measured with this approach is the 
conversion of the amino acid phenylalanine into tyrosine. If it is possible to collect blood 
samples across organs like brain, muscle, kidney, gut or liver, intracellular metabolism in 
these organs can be estimated. 
A primed constant infusion with stable isotopic amino acid tracers followed by a 
protein meal containing oral isotopes allows calculation of protein synthesis and breakdown, 
and splanchnic extraction. In patients with chronic obstructive pulmonary disease, splanchnic 
extraction following a meal was lower than for healthy controls, net protein synthesis was 
similar for patients and controls relating to the level of available essential amino acids, 
however patients were more anabolic during the meal than controls (Jonker et al. 2014).   
Protein digestibility can be measured by combining a fully labelled protein such as 
15N-spirulina with labelled amino acids in a meal and comparing the ratio of the two in the 
meal to the ratio of the two in blood samples (Engelen et al. 2014) whilst absorption can be 
assessed by feeding D-amino acids, which are absorbed at the same rates as L-amino acids, 
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but cannot be utilized for protein synthesis and therefore escape the gut and liver to be 
measured in plasma samples.  
Fractional protein synthesis and fractional protein breakdown in tissues like brain and 
muscle can be measured using pulsed infusions of different labelled isotopes of the same 
amino acid followed by a single tissue biopsy (Tuvdendorj et al. 2014). 
Pulses of stable isotopes can provide the same information about whole body protein 
synthesis and breakdown in the extracellular pool as a primed constant infusion as well as 
allowing modelling of changes in the intracellular pool (Engelen et al. 2014). In addition by 
using combinations of different isotopes in a pulse not only can protein synthesis and 
breakdown be measured, but also nitric oxide, serotonin and glutathione production, 
myofibrillar and collagen protein breakdown, and transamination and reanimation of various 
amino acids. 
An alternative method for measuring protein synthesis and breakdown in tissue 
samples like muscle and brain is a single intake of heavy water (D2O), which will label fatty 
acids and triglycerides as well as certain amino acids, giving an indication of both fat and 
protein metabolism amongst other things (Wilkinson et al. 2015). 
 
We applied some of the described in models of hepatic failure or in humans with liver 
disease. The changes seen in metabolite concentrations during liver disease need to be 
considered in terms of production, consumption and clearance. For instance, we found that 
plasma arginine concentrations fall in a porcine model of acute liver failure due to increased 
plasma clearance rather than a fall in arginine production (Sharma et al. 2012). Also, blood in 
the stomach, as during a gastric bleed, is eating a protein that lacks the essential amino acid, 
isoleucine. By adding isoleucine enterally or intravenously, will increase liver protein 
synthesis and by that reduce the nitrogen load of that blood meal (Olde Damink et al. 1997). 
We found that using transorgan studies of ammonia flux in patients with liver cirrhosis that 
the portal drained viscera (primarily small intestine) and the kidney produce ammonia whilst 
the liver and muscle remove ammonia from the circulation (Olde Damink et al. 2002). Organ 
specific data can enable better, more targeted approaches, such as showing that cooling both 
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reduces uptake of ammonia and glutamine production in the brain (Jalan et al. 2004) and that 
a simulated blood meal stimulates renal ammonia production (Olde Damink et al. 2003). 
In more recent studies, we used infusions of stable isotopes of metabolites related to 
the compound of interest, for example nitric oxide production has been shown to be reduced 
in septic patients and a stable isotope arginine infusion in sepsis stimulated nitric oxide 
production and reduced protein breakdown (Luiking et al. 2015; Luiking et al. 2009). We 
applied the acute pulse method with labelled phenylalanine or the chronic intake of D2O 
measure protein synthesis in organs like brain (several different parts), liver, gut (different 
parts), muscle etc of rats with chronic bile duct ligation (unpublished Rose et al, 2016). We 
used the phenylalanine constant infusion protocol to measure muscle protein synthesis in 
humans with liver cirrhosis (Tsien et al. 2015). 
In conclusion, the use of stable tracers will advance the knowledge of the disturbed 
pathways during liver failure in animals and humans.  
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Figure Legends 
 
Fig.1 13C spectroscopy of rat brain at 9.4T using polarization transfer (DEPT), following 
infusion of [1,6-13C2] glucose. A) Axial MR image of the rat brain showing the localization 
of the 320 μl voxel used for 13C spectroscopy and the position of the 1H quadrature/13C 
linearly polarized surface coil. B) Typical localized brain 13C spectrum acquired during 1 
hour, 4 hours after the onset of glucose infusion. C) Quantified 13C fractional enrichment of 
the positions C4, C3 and C2 of glutamate and glutamine, measured with 10 minutes temporal 
resolution and averaged over the BDL rat group (n = 7). 
 
Fig.2 Summary of the porcine model of acute liver failure (a) and the miRNA results (b).  
Values are means ± SE of relative expression (2-ΔΔCt) for APAP-treated animals (n=6) to both 
the endogenous control (miR26a) and the time-matched control animals (n=3).  P < 0.05: * 
miR122 vs. baseline at -20h; # miR192 vs. baseline at -20h; $ miR124-1 vs. baseline at -8h 
(Baker et al. 2015). 
 
Fig.3 Development of overt hepatic encephalopathy in patients with non-TACC 
haplotype in GLS gene. The critical flicker frequency test with threshold at 39 Hz enabled 
the prediction of development of overt hepatic encephalopathy. 
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Figure 1
Plasma global miRNA levels: 
• Time dependent increase starting 4h prior to ALF 
• Associated with worsening clinical markers of ALF progression 
• Increase found in the protein-bound rather than exosome pool 
• Associated with increasing plasma DAMP levels 
Brain – miR124-1: 
• Increased pre-terminally 
• Associated with decreasing CPP 
Liver – miR122: 
• Increased at onset of ALF 
• Associated with increasing INR 
A 
B 
Kidney – miR192: 
• Increased 8h after ALF 
• Associated with increasing creatinine 
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